Analysts Are Bullish on Top Healthcare Stocks: Heron Therapeutics (HRTX), Chiasma (CHMA)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics (HRTX) and Chiasma (CHMA) with bullish sentiments.

Heron Therapeutics (HRTX)

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Heron Therapeutics, with a price target of $40. The company’s shares closed yesterday at $18.28, close to its 52-week low of $16.20.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $45.20 average price target, representing a 147.3% upside. In a report issued on May 1, Northland Securities also maintained a Buy rating on the stock with a $55 price target.

See today’s analyst top recommended stocks >>

Chiasma (CHMA)

Cantor Fitzgerald analyst Brandon Folkes reiterated a Buy rating on Chiasma yesterday and set a price target of $18. The company’s shares closed yesterday at $6.20, close to its 52-week high of $7.19.

Folkes noted:

“: Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher.”

According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.9% and a 33.7% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

Chiasma has an analyst consensus of Strong Buy, with a price target consensus of $15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts